article Open AccessTop 1% cited

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

British Journal of Clinical Pharmacology · 2007 · Vol. 64(3) · pp. 292–303

Joachim Stangier✉(Boehringer Ingelheim (Germany))Karin Rathgen(Boehringer Ingelheim (Germany))Hildegard Stähle(Boehringer Ingelheim (Germany))Dietmar Ganßer(Boehringer Ingelheim (Germany))Willy Roth(Boehringer Ingelheim (Germany))

View via DOI Full-text PDF

Abstract

These data suggest that dabigatran etexilate is a promising novel oral DTI with predictable PK and PD characteristics and good tolerability. Further investigation of dabigatran etexilate for the treatment and prophylaxis of patients with arterial and venous thromboembolic disorders, acute coronary syndromes and other medical conditions is warranted.

Heparin-Induced Thrombocytopenia and Thrombosis Blood Coagulation and Thrombosis Mechanisms Atrial Fibrillation Management and OutcomesDabigatranPharmacokineticsMedicineTolerabilityPharmacodynamicsPharmacologyPartial thromboplastin timeVolume of distributionDirect thrombin inhibitorThrombin time

MeSH terms

DabigatranAdministration, OralAdolescentAdultAnticoagulantsBenzimidazolesBlood Coagulation TestsDose-Response Relationship, DrugDouble-Blind MethodHumansMaleMiddle AgedPyridinesArea Under Curve

Citations

881

FWCI

33.52

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation